Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation

Stephan A. Grupp; Christopher C. Dvorak; Michael L. Nieder; John E. Levine; Donna A. Wall; Bryan Langholz; Michael A. Pulsipher

doi:10.1002/pbc.24437

Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation

Stephan A. Grupp
, Christopher C. Dvorak
, Michael L. Nieder
, John E. Levine
, Donna A. Wall
, Bryan Langholz
, Michael A. Pulsipher

Research output: Contribution to journal › Review article › peer-review

12 Scopus citations

Abstract

The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.

Original language	English
Pages (from-to)	1044-1047
Number of pages	4
Journal	Pediatric Blood and Cancer
Volume	60
Issue number	6
DOIs	https://doi.org/10.1002/pbc.24437
State	Published - Jun 2013
Externally published	Yes

Keywords

SCT
Stem cell transplantation
Transplantation

Access to Document

10.1002/pbc.24437

Cite this

@article{cb7bca444fd44f70aa6404eb1287cf5d,

title = "Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation",

abstract = "The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.",

keywords = "SCT, Stem cell transplantation, Transplantation",

author = "Grupp, \{Stephan A.\} and Dvorak, \{Christopher C.\} and Nieder, \{Michael L.\} and Levine, \{John E.\} and Wall, \{Donna A.\} and Bryan Langholz and Pulsipher, \{Michael A.\}",

year = "2013",

month = jun,

doi = "10.1002/pbc.24437",

language = "English",

volume = "60",

pages = "1044--1047",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "6",

}

TY - JOUR

T1 - Children's Oncology Group's 2013 blueprint for research

T2 - Stem cell transplantation

AU - Grupp, Stephan A.

AU - Dvorak, Christopher C.

AU - Nieder, Michael L.

AU - Levine, John E.

AU - Wall, Donna A.

AU - Langholz, Bryan

AU - Pulsipher, Michael A.

PY - 2013/6

Y1 - 2013/6

N2 - The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.

AB - The role of SCT in pediatric oncology has continued to evolve with the introduction of new therapeutic agents and immunological insights into cancer. COG has focused its efforts on the study of hematopoietic stem cell transplantation in the treatment of pediatric malignancies in several major multi-institutional Phase II and Phase III studies. These studies include addressing the impact of allogenicity in ALL (ASCT0431), and establishing autologous stem cell transplant as the standard of care in neuroblastoma. Reducing transplant-associated toxicity was addressed in the ASCT0521 study, where the TNFα inhibitor etanercept was tested for the treatment of idiopathic pneumonia syndrome. Impact of cell dose was explored in the single versus tandem umbilical cord blood study CTN-0501, in close collaboration with the BMT-CTN.

KW - SCT

KW - Stem cell transplantation

KW - Transplantation

UR - https://www.scopus.com/pages/publications/84876437018

U2 - 10.1002/pbc.24437

DO - 10.1002/pbc.24437

M3 - Review article

C2 - 23255402

AN - SCOPUS:84876437018

SN - 1545-5009

VL - 60

SP - 1044

EP - 1047

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 6

ER -

Children's Oncology Group's 2013 blueprint for research: Stem cell transplantation

Abstract

Keywords

Access to Document

Fingerprint

Cite this